Your browser is no longer supported. Please, upgrade your browser.
ACST Acasti Pharma Inc. daily Stock Chart
Acasti Pharma Inc.
Index- P/E- EPS (ttm)-0.49 Insider Own- Shs Outstand10.66M Perf Week16.28%
Market Cap15.99M Forward P/E- EPS next Y- Insider Trans- Shs Float5.33M Perf Month10.29%
Income- PEG- EPS next Q- Inst Own- Short Float0.04% Perf Quarter4.17%
Sales0.15M P/S105.11 EPS this Y- Inst Trans- Short Ratio0.30 Perf Half Y-34.78%
Book/sh2.12 P/B0.71 EPS next Y- ROA- Target Price21.91 Perf Year-95.71%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.20 - 41.99 Perf YTD-41.18%
Dividend- P/FCF- EPS past 5Y0.00% ROI- 52W High-96.43% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low25.00% ATR0.11
Employees7 Current Ratio- Sales Q/Q-82.40% Oper. Margin- RSI (14)55.51 Volatility8.00% 6.11%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.06 Prev Close1.49
ShortableYes LT Debt/Eq- EarningsApr 12 Payout- Avg Volume7.42K Price1.50
Recom2.00 SMA2010.13% SMA504.82% SMA200-83.86% Volume430 Change0.67%
May-25-16 06:05PM  Acasti reports 4Q loss +18.44%
05:00PM  Acasti Announces Fourth Quarter and Fiscal Year Results Marketwired
May-12-16 08:08AM  Jan D'Alvise Appointed President & CEO of Acasti Pharma Marketwired +5.79%
Mar-25-16 02:02PM  Nasdaq Grants Acasti Cure Period to Regain Compliance with Audit Committee Membership Requirements Marketwired
Mar-01-16 08:00AM  Acasti Announces Management Appointment and Changes to the Board of Directors Marketwired
Feb-05-16 05:30PM  Acasti Announces Share-for-Debt Marketwired +5.33%
Jan-20-16 11:15AM  Acasti Pharma, Inc. Earnings Analysis: Q3, 2016 By the Numbers
Jan-12-16 06:24PM  Acasti reports 3Q loss
05:07PM  Acasti Announces Third Quarter Results GlobeNewswire
Jan-07-16 07:11PM  Acasti & Neptune Enter Into Transactional Arrangement & Sign Operational Agreements GlobeNewswire -8.07%
Dec-16-15 12:21PM  Solar and Biotech Stocks Are Leading Todays Gainers at Insider Monkey +56.52%
07:50AM  Acasti Provides Update on CaPre® Development Pathway GlobeNewswire
Dec-08-15 01:12PM  ACASTI PHARMA INC. Financials -13.55%
Dec-01-15 07:30AM  Acasti Granted Composition & Use Patent in Japan, Taiwan and Mexico GlobeNewswire
Oct-14-15 05:45PM  Acasti reports 2Q loss -89.35%
05:10PM  Acasti Announces Second Quarter Results GlobeNewswire
07:03AM  Splits Calendar: Acasti Pharma splits before market open today (1:10 ratio)
Sep-29-15 07:00AM  Acasti Announces 1-for-10 Reverse Stock Split GlobeNewswire -22.36%
Aug-19-15 05:05PM  Acasti Announces Grant of Stock Options GlobeNewswire
Aug-05-15 05:30PM  Mario Paradis Appointed CFO of Neptune and Acasti GlobeNewswire
Jul-13-15 05:05PM  Acasti Announces First Quarter Results GlobeNewswire +9.09%
Jun-01-15 07:30AM  Acasti Announces Grant of Stock Options GlobeNewswire
May-27-15 05:37PM  Acasti Announces Fourth Quarter and Fiscal Year Results GlobeNewswire
05:35PM  Acasti Announces New Board of Director Nominees for Election at Annual and Special Meeting of Shareholders GlobeNewswire
May-11-15 10:48AM  Acasti Receives Extension to Regain Compliance With NASDAQ Minimum Bid Price Rule GlobeNewswire
Apr-29-15 06:34PM  Acasti Announces Departure of Chief Financial Officer GlobeNewswire -7.83%
Mar-25-15 07:30AM  Acasti Granted Composition & Use Patent in China GlobeNewswire
Mar-23-15 07:05PM  USPTO Issues Positive Decision That Triggers Royalty Payments to Neptune GlobeNewswire
Mar-02-15 07:30AM  Acasti Receives Full Data for Phase II TRIFECTA Trial GlobeNewswire -5.45%
Feb-26-15 02:24PM  Acasti Pharma Gains Ahead Of Expected Phase II Results +6.02%
Feb-05-15 07:28AM  Dr. Tina Sampalis Appointed Medical Science Liaison for Neptune GlobeNewswire
Jan-13-15 05:05PM  Acasti Announces Third Quarter Results GlobeNewswire -7.16%
Nov-11-14 08:00AM  Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements GlobeNewswire
Oct-20-14 07:59AM  Acasti Announces Grant of Stock Options GlobeNewswire
Oct-15-14 05:03AM  Acasti posts 2Q loss -5.96%
Oct-14-14 07:53AM  Acasti Announces Second Quarter Results GlobeNewswire -21.49%
07:52AM  Neptune Announces Second Quarter Results GlobeNewswire
Sep-30-14 08:00AM  Acasti Announces Positive Top-Line Pharmacokinetic Results GlobeNewswire
Sep-29-14 08:00AM  Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C GlobeNewswire -20.20%
Aug-13-14 01:10PM  Mallinckrodt Beats on Q3 Earnings and Revenues, Ups View
Jul-24-14 07:45AM  Acasti Pharma (ACST) Jumps: Stock Moves 7.3% Higher
07:00AM  Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston GlobeNewswire
Jul-15-14 05:48PM  Acasti Announces First Quarter Results GlobeNewswire
Jul-10-14 06:48AM  Acasti Pharma Inc. (ACST) Jumps: Stock Rises 7.6%
Jul-09-14 11:48AM  Why Acasti Pharmaceuticals (ACST) Stock Is Up Today at TheStreet +7.57%
08:00AM  Acasti Completes Phase II Double Blind (TRIFECTA) and Pharmacokinetic Trials GlobeNewswire
Jun-26-14 04:13PM  Acasti Grants of Stock Options to Newly Appointed Board Members Marketwired
Jun-23-14 07:07AM  Acasti Pharma Inc (ACST) Jumps: Stock Rises 7.2% in Session Zacks -5.04%
Jun-20-14 09:45AM  Acasti Reports Results of Annual and Special Meeting GlobeNewswire +7.21%
Jun-16-14 07:00AM  Acasti Announces Resignation of Chief Financial Officer GlobeNewswire
03:42AM  Acasti Pharma (ACST) Soars: Stock Adds 10.0% in Session Zacks
May-30-14 08:00AM  Neptune, Acasti and NeuroBioPharm Announce Litigation Regarding its Former Chief Executive Officer Marketwired
May-23-14 08:00AM  Neptune, Acasti and NeuroBioPharm Announce Appointment of Interim CEO GlobeNewswire
May-21-14 05:29PM  Acasti Announces Fourth Quarter and Fiscal Year Results GlobeNewswire -6.47%
May-01-14 08:29AM  Acasti to Present at Two Scientific Forums GlobeNewswire
Apr-28-14 08:00AM  Neptune, Acasti and NeuroBioPharm Announce Resignation of Chief Executive Officer GlobeNewswire
Apr-27-14 08:32PM  Neptune and Enzymotec Conclude Final Patent Infringement Settlement and License Agreement GlobeNewswire
Apr-15-14 08:57AM  Activist Trying To Unlock A Potential 65% Upside In Neptune at Seeking Alpha
Apr-01-14 02:24PM  Neptune & Acasti Give Update on Patent Litigations With Enzymotec GlobeNewswire
08:27AM  Acasti Pharma: An Undervalued Biotech With A Potential Best-In-Class Omega-3 Drug at Seeking Alpha
Mar-18-14 09:41PM  4 Stocks Under $10 to Trade for Breakouts at TheStreet
Feb-21-14 10:00AM  Chen Lin's Perfect Biotech Market Prescription: Buy Low, Sell High at Seeking Alpha
Feb-14-14 09:52AM  Neptune and Acasti Provide Update on Patent Litigations With Enzymotec GlobeNewswire
09:40AM  Acasti and Neptune Provide Update on Patent Litigations with Enzymotec GlobeNewswire
Feb-07-14 08:00AM  Acasti Announces Closing of CAD$2.15 Million Private Placement GlobeNewswire
Feb-06-14 03:15PM  5 Stocks Under $10 Set to Soar at TheStreet
Jan-21-14 11:46AM  Neptune Erecting A Moat In Omega-3; Shares Undervalued at Seeking Alpha
Jan-14-14 07:30AM  Acasti Announces Third Quarter Results GlobeNewswire
Jan-11-14 08:34AM  While Amarin Continues To Go Rancid, Neptune Will Soar at Seeking Alpha
Jan-09-14 07:30AM  FDA Clears Acasti's Investigational New Drug Submission to Conduct PK Trial GlobeNewswire
Dec-19-13 07:30AM  Acasti Appoints Jerald J. Wenker as Special Advisor and Nominee to Its Board of Directors GlobeNewswire
Dec-17-13 08:45AM  Neptune, Acasti reach patent settlement and license pact with Aker BioMarine
08:30AM  Neptune and Aker BioMarine Reach Patent Infringement Settlement and License Agreement GlobeNewswire
Dec-16-13 06:07PM  Nasdaq stocks posting largest volume increases AP
Dec-10-13 05:01PM  Acasti Pharma: 7 Different Insiders Have Purchased Shares This Month at Seeking Alpha
Dec-03-13 10:14AM  Acasti Announces Closing of US$23 Million Underwritten Offering of Units GlobeNewswire
Nov-27-13 09:22AM  InPlay: Acasti Pharma prices public offering of 16 mln units of Acasti at $1.25 per Unit, each Unit consisting of one Class A share and one Common Share purchase warrant of Acasti
09:19AM  Acasti Announces Pricing of US$20 Million Offering of Units GlobeNewswire
Nov-26-13 04:01PM  Acasti Announces Proposed Offering of Units GlobeNewswire
Nov-11-13 08:30AM  Acasti Completes PK IND Submission GlobeNewswire
Nov-05-13 08:30AM  Reed V. Tuckson, M.D. Joins Acasti's Board of Directors GlobeNewswire
Oct-29-13 08:30AM  Acasti Strengthens Its IP Portfolio GlobeNewswire
Oct-15-13 08:00AM  Acasti Announces Second Quarter Results GlobeNewswire
Oct-02-13 09:45AM  Patent Infringement Settlements Reached GlobeNewswire
Aug-13-13 07:46PM  4 Healthcare Stock Stories For Tuesday Investment Wellness at Wall St. Cheat Sheet
08:49AM  Acasti announces positive phase 2 open label clinical trial result at
08:40AM  Acasti Announces Positive Phase II Open Label Clinical Trial Results GlobeNewswire
Jul-31-13 08:00AM  Acasti Signs Manufacturing Agreement GlobeNewswire
Jul-15-13 08:00AM  Acasti Announces First Quarter Results GlobeNewswire
Jul-12-13 10:43PM  Neptune Announces Issuance of Shares Under Previously Announced Royalty Prepayment Agreement That Increases Its Equity Participation in Acasti Pharma Inc. GlobeNewswire
Jul-09-13 02:28PM  Acasti Pharma: Increasing Investor Interest And Volatility Likely Cometh at Seeking Alpha
05:10AM  Small-Cap Biotechs With Blockbuster Potential: Hugh Cleland at Seeking Alpha
Jul-03-13 05:38PM  Five 'Red Hot' Biotechs: Chen Lin at Seeking Alpha
05:38PM  5 'Red Hot' Biotechs: Chen Lin at Seeking Alpha
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment and prevention of various cardiometabolic disorders primarily abnormalities in blood lipids. The company offers ONEMIA, a medical food for the dietary management of omega-3 phospholipids deficiency, and related abnormal lipid profiles and cardiometabolic disorders. It also develops CaPre, a prescription drug candidate for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. Acasti Pharma Inc. distributes ONEMIA through physicians, distributors, and pharmacies in the United States and internationally. The company was incorporated in 2002 and is headquartered in Laval, Canada.